Taken together, detection of KRAS c.35G>A, p.(Gly12Asp) variant using LB that could not be identified with the tissue workflow, molecularly explained the clinically diagnosed overgrowth syndrome in our patient, hereby providing personalized treatment options including MEK inhibitors. The gene discussed is KRAS; the disease is overgrowth syndrome.